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Un-Ho Jin1†, Syng-Ook Lee1†, Catherine Pfent2 and Stephen Safe1,3*Abstract
Background: Patients with ER-negative breast tumors are among the most difficult to treat and exhibit low survival
rates due, in part, to metastasis from the breast to various distal sites. Aryl hydrocarbon receptor (AHR) ligands show
promise as antimetastatic drugs for estrogen receptor (ER)-negative breast cancer.
Methods: Triple negative MDA-MB-231 breast cancer cells were treated with eight AHR-active pharmaceuticals including
4-hydroxtamoxifen, flutamide leflunomide, mexiletine, nimodipine, omeprazole, sulindac and tranilast, and the effects of
these compounds on cell proliferation (MTT assay) and cell migration (Boyden chamber assay) were examined. The role
of the AHR in mediating inhibition of MDA-MB-231 cell invasion was investigated by RNA interference (RNAi) and
knockdown of AHR or cotreatment with AHR agonists. Lung metastasis of MDA-MB-231 cells was evaluated in
mice administered cells by tail vein injection and prometastatic gene expression was examined by immunohistochemistry.
Results: We showed that only the proton pump inhibitor omeprazole decreased MDA-MB-231 breast cancer cell invasion
in vitro. Omeprazole also significantly decreased MDA-MB-231 cancer cell metastasis to the lung in a mouse model (tail vein
injection), and in vitro studies showed that omeprazole decreased expression of at least two prometastatic genes, namely
matrix metalloproteinase-9 (MMP-9) and C-X-C chemokine receptor 4 (CXCR4). Results of RNA interference studies
confirmed that omeprazole-mediated downregulation of CXCR4 (but not MMP-9) was AHR-dependent. Chromatin
immunoprecipitation assays demonstrated that omeprazole recruited the AHR to regions in the CXCR4 promoter that
contain dioxin response elements (DREs) and this was accompanied by the loss of pol II on the promoter and
decreased expression of CXCR4.
Conclusions: AHR-active pharmaceuticals such as omeprazole that decrease breast cancer cell invasion and
metastasis may have important clinical applications for late stage breast cancer chemotherapy.
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The aryl hydrocarbon receptor (AHR) is a ligand-activated
transcription factor that was first discovered as an intracellu-
lar protein that bound with high affinity to the environmen-
tal toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [1].
Subsequent studies showed that AHR-mediated transcrip-
tion was dependent on formation of a nuclear heterodimer
composed of the AHR and AHR nuclear translocator
(ARNT) proteins [2] that bind AHR responsive elements* Correspondence: ssafe@cvm.tamu.edu
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reproduction in any medium, provided the or(AhREs) on target gene promoters [3]. Initial studies dem-
onstrated that TCDD and structurally-related halogenated
aromatic compounds induced a well-defined subset of genes
and toxic responses [4]. However, it is now apparent that
this receptor plays a critical endogenous role in cellular
homeostasis and multiple diseases and binds not only toxi-
cants but also endogenous biochemicals, dietary flavonoids
and several phytochemicals associated with health benefits,
other synthetic/industrial chemicals, and many pharmaceu-
ticals [5-7]. The important role of the AHR and effects of
AHR agonists or antagonists have been documented for
various inflammatory conditions, stem cell stability and
expansion, autoimmune diseases, and several different
cancers and clearly demonstrate that this receptor is an
important drug target [8-15].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lecular mechanisms of inhibitory AHR-estrogen receptor
(ER) crosstalk and development of selective AHR modu-
lators (SAhRMs) for treatment of ER-positive breast can-
cer [16,17]. 6-Methyl-1,3,8-trichlordibenzofuran (6-MCDF)
was initially developed as a relatively non-toxic AHR an-
tagonist that inhibited TCDD-induced toxicity in rodent
models [18-22]. However, this compound also exhibited
AHR agonist activity and activated inhibitory AHR-ERα
crosstalk in breast cancer cells and decreased mammary
tumor growth in vivo [17,23,24]. Subsequent studies
showed that MCDF also blocked growth of ER-negative
breast cancer cells [25] and inhibited metastasis of triple
negative MDA-MB-231 breast cancer cells to the lung by
inducing the antimetastatic microRNA-335 (miR-335) [26].
Recent studies showed that eight AHR-active pharmaceuti-
cals including 4-hydroxtamoxifen, flutamide leflunomide,
mexiletine, nimodipine, omeprazole, sulindac and tranilast
exhibited structure- and cell context-dependent AHR
agonist/antagonist activities in BT474 and MDA-MB-468
cells and several of these compounds also inhibited MDA-
MB-468 cell migration [27]. These results are typically ob-
served for selective AhR modulators (SAhRMs) that ex-
hibit tissue- and response-specific AhR agonist or
antagonist activity due to differential expression of co-
factors, different receptor/ligand conformations and
epigenetic effects [16]. Selective receptor modulators
are also commonly observed for nuclear receptors such
as the estrogen receptor (ER) and selective ER modula-
tors have been extensively characterized for treatment
of ER-positive breast cancer [28].
In this study, we initially used the same set of AHR-
active pharmaceuticals in triple-negative MDA-MB-231
cells with a primary objective of identifying a known
pharmaceutical that may be effective for inhibiting breast
cancer metastasis. Among the eight compounds, only
omeprazole inhibited MDA-MB-231 breast cancer cell in-
vasion and this response could be reversed, in part, by
AHR antagonists or by knockdown of the AHR by RNA
interference (RNAi). Omeprazole also inhibited lung me-
tastasis of MDA-MB-231 cells (tail vein injection) in a
mouse model and the antimetastatic pathway was linked
to decreased expression of MMP-9 and AHR-dependent
suppression of the pro-metastatic gene CXCR4. Decreased
invasion and CXCR4 expression was also observed in
MCF-7 and SKBR3 breast cancer cell lines treated with
omeprazole. Thus, omeprazole may have potential clinical
applications for inhibition of breast cancer metastasis due,
in part, to its AHR agonist activity.
Methods
Cell lines, antibodies, and reagents and MTT assay
MDA-MB-231, MCF-7, SKBR3 and MDA-MB-468 hu-
man breast cancer cell lines were obtained from theAmerican Type Culture Collection (Manassas, VA). Cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) nutrient mixture supplemented with 0.22% so-
dium bicarbonate, 0.011% sodium pyruvate, 10% fetal
bovine serum (FBS), and 10 ml/L 100× antibiotic/anti-
mycotic solution (Sigma-Aldrich, St. Louis, MO). Cells
were maintained at 37°C in the presence of 5% CO2, and
the solvent (dimethyl sulfoxide, DMSO) used in the
experiments was ≤0.2%. CYP1A1, AHR, PCNA, and
β-actin antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), and CXCR4 and RNA
polymerase II antibody were purchased from GeneTex
(Irvine, CA). All compounds used in this study and
reagents for cell staining and MTT assay were purchased
from Sigma-Aldrich. Cells (5 × 103 per well) were plated
in 96-well plates and allowed to attach for 16 hr, and
the effects of various AHR-active compounds on cell
proliferation were determined in an MTT assay as previ-
ously described [27].
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using ChIP-IT Express
Magnetic Chromatin Immunoprecipitation kit (Active
Motif, Carlsbad, CA) according to the manufacturer’s
protocol. MDA-MB-231 cells (5 × 106 cells) were treated
with TCDD or omeprazole for 2 hr, and the ChIP assay
was carried out as previously described [27]. The CXCR4-
123 primers were 5′- ATC CCT GGC ATT TCA TCT
CTC C-3′ (sense) and 5′- ACA ACA CCG TGT GGG
TAT TAC C-3′ (antisense) and the CXCR4-4 primers
were 5′- ACT CAC TAC CGA CCA CCC GC-3′ (sense)
and 5′- CGT CAC TTT GCTACC TGC TGC C-3′ (anti-
sense), and then respectively amplified a 171-bp and 232-
bp region of human CXCR4 promoter which contained
the AHR binding sequences. The cytochrome P4501A1
(CYP1A1) primers were 5′-TCA GGG CTG GGG TCG
CAG CGC TTC T-3′ (sense), and 5′-GCT ACA GCC
TAC CAG GAC TCG GCA G-3′ (antisense), and then
amplified a 122-bp region of human CYP1A1 promoter
which contained the AHR binding sequences [27]. PCR
products were resolved on a 2% agarose gel in the pres-
ence of ETBR.
Quantitative real-time PCR
cDNA was prepared from the total RNA of cells using
High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Foster City, CA) as previously described [27]. Values for
each gene were normalized to expression levels of
TATA-binding protein. The sequences of the primers
used for real-time PCR were as follows: CYP1A1 sense
5′- GAC CAC AAC CAC CAA GAA C-3′, antisense 5′-
AGC GAA GAA TAG GGA TGA AG-3′; cytochrome
P4501B1 (CYP1B1) sense 5′- ACC TGA TCC AAT
TCT GCC TG-3′, antisense 5′- TAT CAC TGA CAT
Table 1 AHR-active pharmaceuticals as AHR agonists in
MDA-MB-231 breast cancer cells
AHR agonist mRNA Protein
CYP1A1 CYP1B1 CYP1A1 AHR
40-Hydroxytamoxifen >50 >50 ni decreased
Sulindac <50 >50 ni decreased
Flutamide <50 >50 ni unchanged
Tranilast <50 <50 ind decreased
Leflunomide <50 >50 ind decreased
Nimodipine <50 >50 ind decreased
Mexiletine <50 >50 ind decreased
Omeprazole <50 <50 ind decreased
>50 + <50 are the % of TCDD-induced, response (100%).
ni = no induction; md = induction.
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CGG AAA CAG GG-3′, antisense 5′- GTT ACC ATG
GAG GGG ATC AG-3′; MMP-9 sense 5′- TTG GTC
CAC CTG GTT CAA CT-3′, antisense 5′- ACG ACG
TCT TCC AGT ACC GA-3′; and TBP sense 5′-TGC
ACA GGA GCC AAG AGT GAA-3′, antisense 5′-CAC
ATC ACA GCT CCC CAC CA-3′.
Western blot analysis
Cells (3 × 105) were plated in 6-well plates in DMEM
media containing 2.5% FBS for 16 hr and then treated
with different concentrations of the compounds, and
whole cell lysates were analyzed by western blots essen-
tially as described [27].
Scratch and invasion assay
After cells were more than 80% confluent in 6-well
plates, the scratch was made using a sterile pipette and
then treated with vehicle (DMSO) or compounds. Cell
migration into the scratch was determined after 18 hr
(7-8 determinations/treatment). For invasion assay of
MDA-MB-231 cells, the BD-Matrigel Invasion Chamber
(24-transwell with 8 μm pore size polycarbonate mem-
brane) was used in a process of modified Boyden cham-
ber assay essentially as described [27].
Transfection of siRNAs and luciferase assays
Cells (2 × 105 cells/well) were plated in 6-well plates in
DMEM media supplemented with 10% FBS. After 16 hr,
the cells were transfected with 100 nM of each siRNA
duplex for 6 hr using Lipofectamine 2000 reagent (Invi-
trogen) following the manufacturer’s protocol essentially
as described [27]. In the AhR knockdown experiments,
cells were transfected with AhR siRNA or a non-specific
(control) oligonucleotide [25-27]. The CXCR4 (NM_003467)
promoter clone (CXCR4 promoter-Gaussia luciferase re-
porter construct containing secreted alkaline phosphatase)
and Secrete-Pair Gaussia Luciferase Assay Kit were pur-
chased from Genecopoeia (Rockville, MD). Cells (4 × 104
cells/well) were plated in 12-well plates in DMEM media
supplemented with 10% FBS and transfection experiments
were carried out as described [27]. A multifunctional micro-
plate reader (FLUOstar OPTIMA) was used to quantitate lu-
ciferase and phosphatase activities, and the luciferase
activities were normalized to alkaline phosphatase activity.
Tail vein injection for metastasis in athymic mice and
immunohistochemistry
Female athymic nude mice (Foxn1nu, ages 6-8 weeks)
were purchased from Harlan Laboratories. Animal work
was approved by the Institutional Animal Care and Use
Committee (IACUC) at Texas A&M University. MDA-
MB-231 cells (1 × 106 cells) in PBS were injected through
the tail vein of nude mice to create pulmonary metastasis,and mice were randomly divided into 2 groups of 6 an-
imals each. Either corn oil (control) or omeprazole
(100 mg/kg/day) in corn oil was orally administered to
each group for 4 weeks, respectively. The lung tissues
were fixed in 10% neutral buffered formalin and fur-
ther examined by routine (H&E) and immonohisto-
chemical staining. Paraffin-embedded lung tissue sections
(5-μm thick) were analyzed for CXCR4 and proliferating
cell nuclear antigen (PCNA) as previously described [27].
Statistics
All of the experiments were repeated a minimum of
three times. The data are expressed as the means ± SE.
Statistical significance was analyzed using either Stu-
dent’s t-test or analysis of variance (ANOVA) with
Scheffe’s test. The results are expressed as means with
error bars representing 95% confidence intervals for
three experiments for each group unless otherwise indi-
cated, and a P value of less than 0.05 was considered sta-
tistically significant.
Results
Omeprazole inhibits MDA-MB-231 cell invasion
Table 1 and Additional file 1: Figure S1, Additional file 2:
Figure S2 and Additional file 3: Figure S3 show that the
eight AHR-active pharmaceuticals differentially activated
CYP1A1 and CYP1B1 mRNA levels in MDA-MB-231
cells, and only 4-hydroxytamoxifen induced > 50% of the
maximal response for both genes compared to 10 nM
TCDD (100% response). Induction of CYP1A1 and
CYP1B1 are prototypical markers of AH-responsiveness
of cells to TCDD and other AHR agonists. Induction of
CYP1A1 protein by these compounds was variable and
4-hydroxytamoxifen did not induce this response. TCDD
typically induces proteasome-dependent degradation of
the AhR and this was observed in MDA-MB-231 cells
(Additional file 3: Figure S3). The effects of the AhR phar-
maceuticals on AhR levels were highly variable, and
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pine, sulindac and 4-hydroxytamoxifen and this did not
correlate with their effects on other measures of Ah-
responsiveness. The variable response patterns observed
for these compounds in MDA-MB-231 cells paralleled
their structure- and cell context-dependent variability as
AHR agonists and antagonists as previously observed in
MDA-MB-468 and BT474 cells [27]. However, treatment
of MDA-MB-231 cells with the AHR-active pharmaceuti-
cals using concentrations of each compound that were not
cytotoxic (≤20% growth inhibitory effect) (Additional file
4: Figure S4) showed that among these compounds, onlyFigure 1 Omeprazole inhibits MDA-MB-231 cell invasion. (a)-(c) MD
pharmaceuticals and TCDD, and MDA-MB-231 cancer cell invasion was d
Methods. (d) Quantitation of drug-induced inhibition of invasion. Experi
are expressed as means ± SE. Significant (p < 0.05) inhibition of invasion200 and 300 μM omeprazole inhibited MDA-MB-231 cell
migration in a Boyden chamber assay (Figure 1).
Inhibition of breast cancer cell invasion and metastasis:
role of the AHR
The role of the AHR in mediating inhibition of MDA-MB-
231 cell invasion was investigated by RNA interference
(RNAi) and cotreatment with AHR agonists. Figure 2A
shows that TCDD- and omeprazole-mediated inhibition of
invasion was significantly reversed in cells transfected with
a small inhibitory RNA against the AHR (siAHR) com-
pared to a control oligonucleotide (siCT). Knockdown ofA-MB-231 cells were treated with omeprazole, other AHR-active
etermined using a Boyden chamber assay as outlined in the
ments outlined in (a)-(c) were determined in triplicate and results
is indicated.
Figure 2 (See legend on next page.)
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Figure 2 Role of the AHR in mediating inhibition of MDA-MB-231 cell invasion by omeprazole. (a) AHR silencing. MDA-MB-231 cells were
transfected with siCtl (control) and siAHR (targeting AHR) oligonucleotides treated with DMSO, TCDD or omeprazole, and effects on cell invasion
were determined in a Boyden Chamber assay as outlined in the Methods. Significant (p < 0.05) inhibition of invasion (*) and reversal of these
effects by siAHR (**) are indicated. Similar results were observed with another siAHR oligonucleotide (data not shown). AHR antagonists
3′,4′-dimethoxy-α-naphthoflavone (b) and 3′-methoxy-4′-nitroflavone (c) block omeprazole-induced effects on invasion. Cells were
treated with DMSO, omeprazole and the AHR antagonists alone or in combination, and cell invasion was determined in a Boyden chamber
assay as outlined in the Methods. Significant (p < 0.05) inhibition of invasion (*) and rescue by the AHR antagonists (**) is indicated. (d) AHR antagonist
and silencing inhibits induction of CYP1A1 mRNA by omeprazole. Cells were treated with DMSO, omeprazole and the antagonists alone or in
combination (right and middle panel) or transfected with siCtl or siAHR and treated with DMSO, TCDD or omeprazole, and CYP1A1 mRNA
levels were determined by real time PCR as outlined in the Methods. Significant (p < 0.05) induction of CYP1A1 (*) and reversal of this effect
(**) are indicated. Results (a - d) are expressed as means ± SE for at least 3 replicate experiments for each treatment group.
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cell invasion, suggesting that the receptor alone inhibited
invasion. Similar results were observed in MDA-MB-231
cells cotreated with omeprazole and the AHR antagonists
3′,4′-methoxy-α-naphthoflavone (Figure 2B) [29] and 3′-
methoxy-4′-nitroflavone (Figure 2C) [30], further confirm-
ing a role for the AHR in mediating the inhibitory effects
of omeprazole on MDA-MB-231 breast cancer cell inva-
sion. As a positive control, we also showed that AHR
knockdown and the AHR antagonists also inhibited induc-
tion of CYP1A1 by TCDD and omeprazole (Figure 2D).
TCDD (10 nM) and omeprazole (200 and 300 μM) sig-
nificantly decreased MDA-MB-231 cell migration in a
scratch assay (Figure 3A) and these results paralleled the
inhibition MDA-MB-231 cell invasion after treatment
with omeprazole. We also screened for expression of
several genes associated with cancer cell invasion and
metastasis and observed that omeprazole and TCDD de-
creased expression of MMP-9 and CXCR4 (Figures 3B),
and the latter pro-metastatic gene has previous been
shown to be repressed by TCDD and other AHR ligands
in breast cancer cells [31-34]. The antimetastatic activity
of omeprazole was also investigated in athymic nude
mice injected (tail vein) with MDA-MB-231 cells and
treated with 100 mg/kg/d omeprazole for 28 days.
Treatment-related weight loss was not observed, and
H&E staining was used to evaluate and quantify the total
number of tumor cells relative to the number of pneu-
mocytes. In vehicle control mice, 9,785 tumor cells were
counted in fifty frames with 46,653 pneumocytes (21.0%),
whereas in omeprazole-treated mice, 3,552 tumor cells
were counted with 43,086 pneumocytes (8.2%). These re-
sults demonstrate that omeprazole significantly inhibited
lung metastasis of MDA-MB-231 cells by tail vein injec-
tion and this is illustrated in Figure 3C. Lung tumors were
also immunostained for CXCR4 and PCNA (Figure 3D)
and the decreased expression of both markers in the me-
tastasized tumors in omeprazole-treated mice, suggesting
that omeprazole also directly affected these tumors after
metastasis to the lung.
Omeprazole also induced CYP1A1 and decreased
CXCR4 mRNA levels in MCF-7 and MDA-MB-468 cells(Figure 4A). Knockdown of the AHR in these cell lines
decreased AHR mRNA levels and significantly reversed
omeprazole-mediated induction of CYP1A1 (Figure 4B)
and inhibition of CXCR4 (Figure 4C) mRNA levels in
both cell lines. Omeprazole inhibits MDA-MB-468 cell
migration [27]; however, this cell line did not exhibit in-
vasion. PMA induced invasion of MCF-7 cells and this
response was inhibited by omeprazole and partially re-
versed in cells transfected with siAHR (Figure 4C). Thus,
the effects of omeprazole in the two AH-responsive
MCF-7 and MDA-MB-468 cell lines were similar to that
observed in MDA-MB-231 cells.
Repression of CXCR4 expression by omeprazole is
AHR-dependent
Results in Figure 5A show that omeprazole and TCDD
decreased expression of CXCR4 mRNA levels in MDA-
MB-231 cells and this was partially reversed in cells
transfected with siAHR, and similar results were ob-
served for CXCR4 protein. Omeprazole and TCDD de-
creased MMP-9 activity (by zymography and mRNA);
however, AHR silencing did not attenuate downregula-
tion of MMP-9 mRNA levels (Figure 5B, right panel),
suggesting that downregulation of MMP-9 was AHR-
independent. TCDD and omeprazole decreased lucifer-
ase activity in MDA-MB-231 cells transfected with the
CXCR4-luc construct which contains the -1121 to +95
region of the CXCR4 promoter (Figure 5C). TCDD- and
omeprazole-induced downregulation of luciferase activ-
ity was significantly reversed in cells cotransfected with
siAHR or cotreated with the AHR antagonist 3′4′-
dimethoxy-α-naphthoflavone (Figure 5C), confirming a
role for the AHR in mediating this response. The role of
CXCR4 downregulation in mediating the inhibitory ef-
fects of omeprazole on MDA-MB-231 cell invasion was
supported by results showing that knockdown of CXCR4
by RNAi also decreased invasion of MDA-MB-231 cells
(Figure 5D).
The proximal Ah-responsive region of the CXCR4
promoter contains 4 putative DREs with a core GCGTG
AHR complex binding motif (Figure 6A), and primers
for the upstream DRE-123 and downstream DRE-4
Figure 3 (See legend on next page.)
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Figure 3 Omeprazole inhibits migration and invasion in vitro and metastasis in vivo. (a) Migration. MDA-MB-231 cells were treated with
DMSO, TCDD or omeprazole, and cell migration was determined using a scratch assay as outlined in the Methods. (b) Decreased MMP-9 and
CXCR4 expression. MDA-MB-231 cells were treated with DMSO, TCDD or omeprazole, and MMP-9 and CXCR4 mRNA levels were determined by
real time PCR as outlined in the Methods. Results are means ± SE for at least 3 replicate determinations and significant (p < 0.05) inhibition is
indicated. H&E staining (c) and immunostaining (d) of lung tissue from in vivo studies. Lung tissue sections from animals treated with
corn oil (control) or omeprazole (100 mg/kg/d) were obtained for H&E and immunostaining as outlined in the Methods. Image magnification
40×; inset magnification 100 × .
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cruitment or loss of AHR binding in a ChIP assay.
Omeprazole (100-300 μM) clearly induced AHR binding
to DRE-123 and DRE-4 and, in the untreated cells, bind-
ing of this receptor was not observed at either DRE site
(Figure 6B). The comparative effects of 10 nM TCDD
and 200 μM omeprazole on inducing AHR binding to
DRE-123 and DRE-4 in the CXCR4 promoter and the
CYP1A1 DRE was also investigated in MDA-MB-231
cells, and both ligands induced AHR binding at all 3 cis-
DRE motifs (Figure 6C). In contrast, omeprazole and
TCDD decreased binding of pol II to the CXCR4 pro-
moter but increased pol II binding to the CYP1A1 gene
promoter and this corresponded to the ligand-mediated
suppression and induction of these genes, respectively.
Recruitment of the corepressor SMRT to the CXCR4
promoter was not observed (data not shown), and the
role of other nuclear cofactors in mediating AHR-
dependent downregulation of CXCR4 by TCDD and
omeprazole is currently being investigated.
Discussion
The treatment and prognosis for breast cancer patients
depends on multiple tumor characteristics including the
size, stage, extent of tumor delocalization, and expres-
sion of various protein and mRNA prognostic factors
[35]. Patients that express ERα can be successfully
treated with antiestrogens and aromatase inhibitors, and
more aggressive tumors that overexpress the epidermal
growth factor receptor 2 (ErbB2) oncogene can be
treated with the ErbB2 neutralizing antibody in combin-
ation therapies [36]. Patients with ER-negative tumors
are among the most difficult to treat and exhibit low
survival rates due, in part, to metastasis from the breast
to various distal sites.
Research in this laboratory and others [33,34] have
demonstrated that the AHR is a potential drug target for
treating ER-negative breast cancer. For example, the
SAhRM MCDF acts as an AhR agonist to inhibit growth
and/or metastasis of ER-negative breast tumors in ani-
mal models, and this was associated with induction of
microRNA-335 and the subsequent suppression of the
pro-metastatic SOX4 gene [26]. Several other studies
with structurally diverse AHR ligands (agonists) demon-
strated AHR-mediated inhibition of cell migration and/or invasion in ER-negative breast cancer cells and these
responses were also accompanied by enhanced differen-
tiation and downregulation of pro-metastatic genes such
as CXCR4 and MMP-9 [31-34,37-39].
A number of pharmaceutical agents approved for
multiple uses are also AHR ligands, and some of these
compounds including 4-hydroxytamoxifen and trani-
last exhibit some anticancer activity in breast cancer
cells [37-39]. Our initial studies investigated the AHR
agonist activities of eight AHR-active pharmaceuticals
including tranilast and 4-hydroxytamoxifen in MDA-
MB-468 and BT474 breast cancer cells and observed
that their AHR activity was structure-, cell context-
and response-specific [27]. This variability in activity is
illustrated by results for mexiletine which was an AHR
antagonist in MDA-MB-468 cells and inhibited TCDD-
induced CYP1A1 gene expression but was a partial AHR
agonist in BT474 cells [27]. Moreover, in ER-negative
MDA-MB-468 cells, several of the AHR pharmaceuticals
including flutamide, leflunomide, nimodipine, omeprazole,
sulindac and tranilast inhibited cell migration [27]. In this
study, we primarily focused on the effects of the AHR-
active pharmaceuticals in the more aggressive MDA-MB-
231 cell line which exhibits high basal rates of migration
and also invasion in in vitro assays. However, we also ob-
served that omeprazole induced CYP1A1 in MCF-7 and
MDA-MB-468 cells (Figure 4A) [27]. The effects of the
AHR-active pharmaceuticals on CYP1A1 and CYP1B1 ex-
pression in MDA-MB-231 cells were similar (Table 1);
however, only omeprazole inhibited MDA-MB-231 cell
invasion (Figures 1D and 2A) and we therefore se-
lected this widely used proton pump inhibitor for fur-
ther evaluation as an AHR-active antimetastatic agent
in breast cancer. Previous studies suggest that omepra-
zole exhibits anti-inflammatory activity [40] and anti-
cancer activity, particularly in combination treatment
studies [41-43]. Since this investigation focused pri-
marily on the effects of omeprazole alone, higher con-
centrations that were not cytotoxic were used in the
cell culture experiments. Previous in vivo studies used
an omeprazole dose of 75 mg/kg for administration of
drug combinations and this dose had no effect on
tumor growth [41]. A 100 mg/kg (daily) dose was used
for investigating the in vivo antimetastic activity of
omeprazole (Figure 3C,D).
Figure 4 Role of omeprazole and the AHR in downregulation of CXCR4 and inhibition of invasion in MCF-7 and MDA-MB-468 cells.
(a) CYP1A1 and CXCR4 mRNA. Cells were treated with 100 or 200 μM omeprazole for 24 hr, and CXCR4 and CYP1A1 mRNA levels were determined
as outlined in the Methods. (b) and (c) Role of the AHR. Cells were transfected with siAHR and treated with 200 μM omeprazole, and expression of
AHR and CYP1A1 (b) and CXCR4 (c) mRNA levels were determined as outlined in the Methods. MCF-7 cells were also cotreated with 100 nM PMA.
(d) Effects of omeprazole on invasion of MCF-7 cells. Cells were transfected with siCtl (non-specific) or siAHR and treated with DMSO or 200 μM
omeprazole plus PMA (MCF-7 cells), and cell invasion was determined in a Boyden chamber assay as outlined in the Methods. Results (a-d) are
means ± SE for at least 3 replicate determinations for each data point. Significantly (p < 0.05) increased CYP1A1 or decreased CXCR4 (*) and reversal
of these effects by siAHR (**) are indicated. AHR mRNA was significantly (p < 0.05) decreased by siAHR in all 3 cell lines.
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Figure 5 Omeprazole and TCDD decrease CXCR4 and MMP-9. (a) CXCR4 mRNA and protein. MDA-MB-231 cells were treated with DMSO,
omeprazole or TCDD and transfected with siCtl (control) or si AHR, and mRNA and protein levels were determined as described in the Methods.
(b) Effects on MMP-9. Cells were treated with DMSO, TCDD or omeprazole, and MMP-9 activity (zymography) and MMP-9 mRNA levels (in cells
transfected with siCtl or siAHR) were determined as outlined in the Methods. (c) CXCR4 promoter activity. MDA-MB-231 cells were transfected
with CXCR4-(-1121 to +95)luc and either cotransfected with siCtl and siAHR or treated with 3′,4′-dimethoxy-α-naphthoflavone and luciferase
activity determined as outlined in the Methods. (d) Silencing of CXCR4. Cells were transfected with siCtl or siCXCR4 and effects on cancer cell
invasion and CXCR4 expression were determined as outlined in the Methods. Results (a-d) are means ± SE for at least 3 experiments and
significant (p < 0.05) decrease (*) or rescue (**) is indicated.
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Figure 6 ChIP assays and AHR-DRE binding. (a) Schematic outline of DRE-123 and DRE-4 on the CXCR4 promoter. ChIP analysis of (b) omepra-
zole and (c) omeprazole and TCDD-induced interactions with the DRE-123, DRE-4 and CYP1A1-DRE cis-elements. MDA-MB-231 cells were treated
with DMSO, omeprazole and TCDD, and binding to various DRE elements was determined in ChIP assays as described in the Methods.
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gration and invasion (Figures 2A and 3A) and this re-
sponse was attenuated after knockdown of the AHR
by RNAi or after cotreatment with AHR antagonists
(Figure 2A-C). MDA-MB-468 cells did not exhibit
invasion; however, omeprazole inhibited PMA-induced
invasion of MCF-7 cells and this response was also attenu-
ated after AHR knockdown (Figure 4D). Moreover, these
in vitro assays were complemented by inhibition of lung
metastasis of MDA-MB-231 cells in mice administered
the cells by tail vein injection and treated with omeprazole
(Figure 3B). In contrast to the effects observed for MCDF
[26], omeprazole did not induce miR-335 expression in
MDA-MB-231 (data not shown), but significantly de-
creased expression of the pro-metastatic genes MMP-9
and CXCR4 (Figure 5A,B) and similar results were ob-
served in MCF-7 and MDA-MB-468 cells (Figure 4C).
Previous studies show that one or both of these genes
was decreased in ER-positive cells and tumors treated
with structurally diverse AHR ligands [31-34]. We alsoobserved that CXCR4 (and PCNA) expression was also
decreased in metastasized tumors (lung) (Figure 3D), sug-
gesting that omeprazole not only decreased metastasis but
directly targeted CXCR4 and PCNA in the metastasized
tumors. We further investigated the role of the AHR in
mediating the induction of MMP-9 and CXCR4 by omep-
razole in MDA-MB-231 cells and our results show that al-
though AHR silencing may decrease MMP-9 activity
(zymography), the loss of the receptor does not attenuate
the effects of omeprazole on MMP-9 (Figure 4B). In con-
trast, omeprazole-induced downregulation of CXCR4 was
significantly reversed by AHR silencing or cotreatment
with AHR antagonists (Figure 5A,C), suggesting that
downregulation of MMP-9 and CXCR4 by omeprazole in
MDA-MB-231 cells is AHR-independent and -dependent,
respectively.
Although the AHR and other nuclear receptors medi-
ate induction and expression of genes, most mechanistic
studies have focused on activation of genes and the
ligand-dependent recruitment of the AHR and nuclear
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[44]. Treatment of MDA-MB-231 cells with omeprazole
or TCDD resulted in recruitment of the AHR to the
CYP1A1 gene promoter and this was accompanied recruit-
ment of pol II (Figure 6C) and induction of CYP1A1 gene
expression (Additional file 1: Figure S1 and Additional file
1: Figure S3). The CXCR4 promoter contains two regions
with cis-elements consistent with DRE sequences (DRE-
123 and DRE-4). Omeprazole decreased luciferase activity
in MDA-MB-231 cells transfected with the pGL3-CXCR4
(-1121 to +95) construct which contains these DREs and
this response was attenuated by AHR silencing or AHR an-
tagonists (Figure 4C). Omeprazole and TCDD also induced
AHR binding to the CXCR4 promoter (Figure 6B,C); how-
ever, in contrast to the recruitment of pol II to the
CYP1A1 promoter, both TCDD and omeprazole decreased
pol II interactions with the CXCR4 promoter (Figure 6C)
and this was consistent with omeprazole-mediated re-
pression of CXCR4 gene expression. We did not ob-
serve ligand-dependent recruitment of the corepressor
SMRT to the CXCR4 promoter and are currently in-
vestigating the role of other nuclear cofactors required
for AHR-mediated suppression of CXCR4 and other
genes in cancer cells treated with omeprazole. Thus,
the anticancer activity of omeprazole is due, in part, to
the AhR but this does not exclude a role for other
AhR-independent pathways.Conclusions
In summary, results of this study demonstrate that
among several AHR-active pharmaceuticals, omeprazole
exhibits antimetastatic activity for triple-negative MDA-
MB-231 breast cancer cells, and CXCR4 is one of the
key target genes not only for omeprazole but also for
other AHR agonists [31-34]. AHR-dependent downregu-
lation of CXCR4 by omeprazole significantly contributed
to the antimetastatic activity of this compound since si-
lencing of CXCR4 by RNAi in MDA-MB-231 cells also
inhibited invasion of these cells in a Boyden chamber
assay (Figure 5D). Since CXCR4 has both functional and
prognostic significance for metastasis in breast tumors
and cells [45], the antimetastatic activity of omeprazole
and other AHR-active pharmaceuticals including other
benzimidazole protein pump inhibitors are currently
being investigated. The anticancer activity of drugs used
for treatment of gastroesophageal reflux disease is not
well established [46] and it is possible that chemother-
apeutic effects of omeprazole for inhibition of breast
cancer metastasis may require higher doses than are
typically used for treating acid reflux. However, lower
doses of omeprazole may be effective for drug com-
bination therapies [41] and these are currently being
investigated.Additional files
Additional file 1: Figure S1. Induction of CYP1A1 mRNA by AHR-active
pharmaceuticals. MDA-MB-231 cells were treated with DMSO, different
concentrations of pharmaceuticals and 10 nM TCDD, and CYP1A1 mRNA
levels were determined by real time PCR as outlined in the Methods.
Results are expressed as means ± SE for 3 replicate determinations.
Additional file 2: Figure S2. Induction of CYP1B1 mRNA by AHR-active
pharmaceuticals. MDA-MB-231 cells were treated with DMSO, different
concentrations of pharmaceuticals and 10 nM TCDD, and CYP1B1 mRNA
levels were determined by real time PCR as outlined in the Methods.
Results are expressed as means ± SE for 3 replicate determinations.
Additional file 3: Figure S3. Effects of AHR-active pharmaceuticals
and TCDD on CYP1A1 and AHR proteins. MDA-MB-231 cells were
treated with DMSO, TCDD and AHR-active pharmaceuticals for 24 hr,
and whole cell lysates were analyzed by western blots as outlined in
the Methods.
Additional file 4: Figure S4. Growth inhibition. MDA-MB-231 cells were
treated with DMSO, different concentrations of AHR-active pharmaceuticals
for 24 hr, and cell growth was determined using MTT assay as outlined in
the Methods. Results are expressed as means ± SE for at least 3 replicate
determinations.
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